VaxGen Submits Proposal to Produce Up to 75 Million Doses of Anthrax Vaccine; Discontinues Plague Vaccine Program
BRISBANE, Calif. - VaxGen announced today that it has submitted a proposal to the U.S. Department of Health and Human Services (HHS) describing its plan to provide up to 75 million doses of its recombinant anthrax vaccine to the U.S. strategic
national stockpile of biodefense products. The HHS has indicated that it intends to award purchase contracts for such a vaccine on or about Aug. 9, 2004.
VaxGen has already received two contracts from the National Institute of
Allergy and Infectious Diseases (NIAID) to develop its recombinant anthrax
vaccine candidate. The contracts are valued at more than $100 million. The
company is also developing an attenuated smallpox vaccine in partnership with
the Chemo-Sero Research Institute (Kaketsuken) of Kumamoto, Japan.
Additionally, VaxGen announced that it has discontinued early-stage
development of a recombinant plague vaccine after the NIAID elected not to
provide research and development funding for this vaccine. The company's
decision will have no effect on the development of its other product
candidates.
VaxGen, Inc. is a biopharmaceutical company engaged in the development,
manufacture and commercialization of biologic products for the prevention and
treatment of human infectious diseases. The company is developing preventive vaccines against anthrax and smallpox, and an anthrax monoclonal antibody in collaboration with Avanir Pharmaceuticals.
Source: VaxGen, Inc.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.
